Liquidia shares halted for volatility after falling 23%
Trading in the pulmonary hypertension drugmaker was paused after a sharp intraday slide, with no confirmed cause yet given by the company.
Published
Liquidia Technologies shares are halted for volatility on Wednesday after falling 23% during the session. The exchange imposed the halt automatically once the decline reached a threshold that regulators use to give both buyers and sellers time to reassess.
Robinhood data show the stock trading between $62.07 and $71.93 during the session, with shares last at $62.27, down 13.4% from the day's high.
Liquidia's main product, Yutrepia, is an inhaled dry-powder version of the drug treprostinil, used to treat pulmonary arterial hypertension, according to Wealth Awesome. The company competes in that market with United Therapeutics. Liquidia has seen sharp swings before: shares fell about 8.5% in August despite a Q2 net income of roughly $74.7 million and revenue near $171.7 million tied to Yutrepia sales, Simply Wall St reported, and dropped 10.5% to $29.20 in a separate move in February, according to Bitget News.
A drop steep enough to trigger a halt suggests sell orders outpaced the stock's available liquidity, a pattern common in shares with a small float and concentrated ownership, where a handful of large trades can move the price disproportionately. The pause gives market makers room to rebuild their order books, but it does not resolve the imbalance behind it. Investors will be watching where the stock reopens and whether trading volume stays elevated afterward, since that will show whether the initial slide was overdone or whether the selling pressure continues.